Pelthos Therapeutics Inc. /
Hatchtech Pty Ltd ACN 098 559 409
Pelthos Therapeutics buys Hatchtech assets in $1.8 million deal
Source for the buyer and target: Pelthos Therapeutics Inc.
For the buyer and target.
“Asset Purchase Agreement, dated as of December 23, 2025, by and between Pelthos Therapeutics Inc., as Purchaser, and Hatchtech Pty Ltd ACN 098 559 409, as Seller.”
Published 2 Jan 2026
Open the sourceWhat happened
Pelthos Therapeutics Inc. purchased assets from Hatchtech Pty Ltd ACN 098 559 409 for $1,800,000. The transaction was consummated on the Closing Date. [01]
The assets include the Xeglyze product, a prescription medication approved by the U.S. Food and Drug Administration in July 2020. Terms include no future milestone, royalty or other payments owed to Hatchtech. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Pelthos Therapeutics buys Hatchtech assets in $1.8 million deal
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“The assets include the Xeglyze product, a prescription medication approved by the U.S. Food and Drug Administration in July 2020”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly